Founded in 1986 to address the specialized needs of the emerging biotechnology industry, Versaggi Biocommunications is one of a handful of specialist in the biotech medical technology industries. It works with clients in every stage of development: from formation and venture capital funding, research and development, through public offerings, clinical trials, and worldwide product marketing.
Charles Versaggi, has more than 18 years experience in the technology communications area, having served as manager of bioindustrial account services for Regis McKenna and as a science reporter for The Milwaukee Journal. Versaggi has directed programs for more than 170 companies including Athena Neurosciences, Becton Dickinson, Chiron, Cetus, Glycomed, Laserscope, Molecular Biosystems and Acuson.
In the mid-1980s Versaggi directed a national media program to ensure that Chiron Corporation received credit and visibility for its role in developing the core technology behind Recombivax HB, the first genetically engineered vaccine for humans, which was being marketed under license by Merck. More recently, the firm executed a national educational program for MicroPulse to expose the under-reported problem of operating room-acquired pressure ulcers and worked with Vysis to develop media campaigns for several of the company's products for genomic disease management, including two key diagnostic products.